120 related articles for article (PubMed ID: 11237799)
1. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.
Bernstein DI; Harrison CJ; Tomai MA; Miller RL
J Infect Dis; 2001 Mar; 183(6):844-9. PubMed ID: 11237799
[TBL] [Abstract][Full Text] [Related]
2. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study.
Spruance SL; Tyring SK; Smith MH; Meng TC
J Infect Dis; 2001 Jul; 184(2):196-200. PubMed ID: 11424018
[TBL] [Abstract][Full Text] [Related]
3. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
Mark KE; Corey L; Meng TC; Magaret AS; Huang ML; Selke S; Slade HB; Tyring SK; Warren T; Sacks SL; Leone P; Bergland VA; Wald A
J Infect Dis; 2007 May; 195(9):1324-31. PubMed ID: 17397003
[TBL] [Abstract][Full Text] [Related]
4. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
Wu JJ; Huang DB; Tyring SK
Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602
[TBL] [Abstract][Full Text] [Related]
5. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
6. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs.
Harrison CJ; Miller RL; Bernstein DI
Antimicrob Agents Chemother; 1994 Sep; 38(9):2059-64. PubMed ID: 7811019
[TBL] [Abstract][Full Text] [Related]
7. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
Harrison CJ; Miller RL; Bernstein DI
Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
9. Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Earwood J; Clark JR; Li Y; Mishra P; Li C; Nayak BP; Miller AT; Wu TY; Cooke MP; Valiante NM
Antivir Chem Chemother; 2014 Apr; 23(5):189-96. PubMed ID: 23232327
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
11. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
12. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
13. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
14. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
15. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
Leone P
Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
[TBL] [Abstract][Full Text] [Related]
17. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
18. Genital shedding of herpes simplex virus among men.
Wald A; Zeh J; Selke S; Warren T; Ashley R; Corey L
J Infect Dis; 2002 Oct; 186 Suppl 1():S34-9. PubMed ID: 12353185
[TBL] [Abstract][Full Text] [Related]
19. Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.
Weinberg A; Konrad M; Merigan TC
J Virol; 1987 Jul; 61(7):2120-7. PubMed ID: 3035213
[TBL] [Abstract][Full Text] [Related]
20. [Herpes simplex virus and malignancies of female genital organs].
Cokić-Damjanović J; Horvat E; Balog A
Med Pregl; 2001; 54(9-10):432-7. PubMed ID: 11876004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
